Company Overview#
NineBioWare is an AI diagnostics company focused on the early detection of neurodegenerative diseases. By combining multi-biomarker blood panels with artificial intelligence, the company aims to identify early signs of conditions such as Alzheimer’s disease (AD) and Parkinson’s disease (PD).
Technology & Product#
The platform combines the FluometricDX reader, a fluorescence-based biosensing device, with the FluoreArray microfluidic cartridge and machine-learning analysis to run ultra-sensitive blood diagnostics. The company is developing spiral microfluidic detection platforms and biomolecule detection devices that use stretchable materials. These platforms capture and analyze fluid samples via antibody-binding complexes to extract complex biomarker profiles for AI analysis.
Market & Use Cases#
NineBioWare’s solutions target clinical laboratories, diagnostic centers, and neurology departments seeking less invasive, blood-based alternatives to traditional neurodegenerative screening methods like cerebrospinal fluid (CSF) taps or expensive PET scans. The technology facilitates early screening and continuous monitoring of AD and PD.
Traction & References#
Founded in late 2022 as a spin-off or research venture at Sungkyunkwan University, NineBioWare has secured foundational intellectual property. The company is co-listed with the Sungkyunkwan University Research & Business Foundation as the applicant for multiple patents, including “Spiral Microfluidic Detection Device” and “Stretchable Biomolecule Detection Device”(K-Knowledge). As an early-stage Pre-seed company, clinical validation and broad commercial adoption metrics are currently in development.
Collaboration Relevance#
The company is relevant for academic research hospitals and pharmaceutical companies looking for blood-based biomarker capabilities to support clinical trials for neurodegenerative disease therapeutics. It is also suitable for diagnostic hardware manufacturers interested in co-developing or licensing novel microfluidic detection platforms.